These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 35848137)

  • 1. Molecular and expressional characterization of tumor heterogeneity in pulmonary carcinosarcoma.
    Ohtaki Y; Kawabata-Iwakawa R; Nobusawa S; Goto Y; Shimizu K; Yajima T; Nakazawa S; Kawatani N; Yoshida Y; Sano T; Shirabe K
    Mol Carcinog; 2022 Oct; 61(10):924-932. PubMed ID: 35848137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic features and genomic analysis of pulmonary blastomatoid carcinosarcoma.
    Zhao J; Xiang C; Zhao R; Guo P; Zheng J; Han-Zhang H; Yu K; Zhang J; Han Y
    BMC Cancer; 2020 Mar; 20(1):248. PubMed ID: 32209061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophageal carcinosarcoma with basaloid squamous carcinoma and rhabdomyosarcoma components with TP53 mutation.
    Amatya VJ; Takeshima Y; Kaneko M; Inai K
    Pathol Int; 2004 Oct; 54(10):803-9. PubMed ID: 15482572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
    Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-Generation Sequencing Analysis Identified Genomic Alterations in Pathological Morphologies of 3 Cases of Pulmonary Carcinosarcoma.
    Li F; Hu S; Kong K; Cao P; Han P; Deng Y; Zhao B
    Onco Targets Ther; 2020; 13():7963-7972. PubMed ID: 32848420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
    Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
    Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.
    Fallet V; Saffroy R; Girard N; Mazieres J; Lantuejoul S; Vieira T; Rouquette I; Thivolet-Bejui F; Ung M; Poulot V; Schlick L; Moro-Sibilot D; Antoine M; Cadranel J; Lemoine A; Wislez M
    Ann Oncol; 2015 Aug; 26(8):1748-53. PubMed ID: 25969368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
    Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.
    Lococo F; Gandolfi G; Rossi G; Pinto C; Rapicetta C; Cavazza A; Cesario A; Galeone C; Paci M; Ciarrocchi A
    J Thorac Oncol; 2016 Aug; 11(8):1282-1292. PubMed ID: 27156442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
    J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-spectrum of
    Basdemirci M; Zamani A; Zamani AG; Findik S; Yildirim MS
    Indian J Cancer; 2022; 59(2):236-243. PubMed ID: 34380837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation sequencing analysis identifies genomic alterations in pathological morphologies: A case of pulmonary carcinosarcoma harboring EGFR mutations.
    Koba H; Kimura H; Nishikawa S; Sone T; Abo M; Hara J; Hosomichi K; Tajima A; Kasahara K
    Lung Cancer; 2018 Aug; 122():146-150. PubMed ID: 30032823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
    Jiang X; Liu Y; Chen C; Zhan Z; Yan Q; Guo Y; Wang Q; Li K
    Clin Lung Cancer; 2012 Jul; 13(4):288-96. PubMed ID: 22169481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
    Vatan O; Bilaloglu R; Tunca B; Cecener G; Gebitekin C; Egeli U; Yakut T; Urer N
    Tumori; 2007; 93(5):473-7. PubMed ID: 18038880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
    Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
    Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Mediastinal Carcinosarcoma With Beta-HCG Production and KRAS Mutation.
    Shaker N; Amadi CC; Welliver M; Otterson GA; Liebner DA; Shilo K
    Int J Surg Pathol; 2023 Dec; 31(8):1598-1604. PubMed ID: 37013353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.